{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:41:18Z","timestamp":1784770878101,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Long-term survivors have an increased risk of developing secondary solid malignancies (SSMs) after allogeneic-hematopoietic stem cell transplantation (allo-HSCT) with graft-versus-host disease (GVHD) potentially modulating these risks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study analyzed the cumulative incidences of SSMs after chemotherapy-based conditioning for allo-HSCT patients with acute myeloid leukemia (n\u2009=\u2009266) transplanted at the University Hospital Regensburg between 1999 and 2016.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median follow-up was 11.4\u00a0years (Interquartile range, 9.0\u201314.9). The 100-day cumulative incidence of grade II-IV acute GVHD (aGVHD) was 44.4% [95%\u00a0CI (38.3, 50.2)], while the 5-year cumulative incidence of chronic GVHD (cGVHD, requiring systemic immunosuppression) was 36.9% [95%\u00a0CI (31.1, 42.6)]. The cumulative incidences of secondary squamous cell carcinomas (SCCs) at 10 and 15\u00a0years were 4.2% [95%\u00a0CI (2.2, 7.2)] and 8.1% [95%\u00a0CI (4.6, 12.8)], while the cumulative incidences of non-SCCs at 10 and 15\u00a0years were 5.4% [95%\u00a0CI (3.1, 8.7)] and 6.9% [95%\u00a0CI (4.0, 10.8)]. Antithymocyte globulin (ATG) was associated with reduced incidences of SCCs but not of non-SCCs. Patients with grade II-IV aGVHD had increased rates of SCCs after adjusting with patient age and ATG, while patients with cGVHD showed only a trend for increased rates of SCCs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The data indicate that aGVHD and cGVHD affect the rates of secondary SCCs. While the use of ATG is associated with lower incidences of SCCs via reduction of GVHD, there was no association of ATG with non-SCCs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05679-5","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T14:01:59Z","timestamp":1711116119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Secondary solid malignancies and precancerous lesions after allogeneic hematopoietic stem cell transplantation using non-total body irradiation-based conditioning in acute myeloid leukemia"],"prefix":"10.1007","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7435-9337","authenticated-orcid":false,"given":"Gruber","family":"Isabella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Appel","family":"Katharina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edinger","family":"Matthias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koelbl","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolff","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"5679_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.2001.19.2.464","volume":"19","author":"S Bhatia","year":"2001","unstructured":"Bhatia S, Louie AD, Bhatia R et al (2001) Solid cancers after bone marrow transplantation. J Clin Oncol off J Am Soc Clin Oncol 19:464\u2013471. https:\/\/doi.org\/10.1200\/JCO.2001.19.2.464","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"5679_CR2","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJM199703273361301","volume":"336","author":"RE Curtis","year":"1997","unstructured":"Curtis RE, Rowlings PA, Deeg HJ et al (1997) Solid cancers after bone marrow transplantation. N Engl J Med 336:897\u2013904. https:\/\/doi.org\/10.1056\/NEJM199703273361301","journal-title":"N Engl J Med"},{"key":"5679_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.oraloncology.2005.02.001","volume":"41","author":"F Demarosi","year":"2005","unstructured":"Demarosi F, Lodi G, Carrassi A et al (2005) Oral malignancies following HSCT: graft versus host disease and other risk factors. Oral Oncol 41:865\u2013877. https:\/\/doi.org\/10.1016\/j.oraloncology.2005.02.001","journal-title":"Oral Oncol"},{"key":"5679_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"5679_CR5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/J.BBMT.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S et al (2005) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945\u2013956. https:\/\/doi.org\/10.1016\/J.BBMT.2005.09.004","journal-title":"Biol Blood Marrow Transplant"},{"key":"5679_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C et al (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10:855\u2013864. https:\/\/doi.org\/10.1016\/S1470-2045(09)70225-6","journal-title":"Lancet Oncol"},{"key":"5679_CR7","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.bbmt.2016.06.020","volume":"22","author":"M Grube","year":"2016","unstructured":"Grube M, Holler E, Weber D et al (2016) Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation\u2014results from a single-center observational study. Biol Blood Marrow Transplant 22:1781\u20131791. https:\/\/doi.org\/10.1016\/j.bbmt.2016.06.020","journal-title":"Biol Blood Marrow Transplant"},{"key":"5679_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M et al (2015) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 21:389-401.e1. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transplant"},{"key":"5679_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kr\u00f6ger","year":"2016","unstructured":"Kr\u00f6ger N, Solano C, Wolschke C et al (2016) Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 374:43\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1506002","journal-title":"N Engl J Med"},{"key":"5679_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","volume":"9","author":"SJ Lee","year":"2003","unstructured":"Lee SJ, Vogelsang G, Flowers MED (2003) Chronic graft-versus-host disease. Biol Blood Marrow Transplant 9:215\u2013233. https:\/\/doi.org\/10.1053\/bbmt.2003.50026","journal-title":"Biol Blood Marrow Transplant"},{"key":"5679_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1200\/JCO.2005.02.7052","volume":"24","author":"W Leisenring","year":"2006","unstructured":"Leisenring W, Friedman DL, Flowers MED et al (2006) Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 24:1119\u20131126. https:\/\/doi.org\/10.1200\/JCO.2005.02.7052","journal-title":"J Clin Oncol"},{"key":"5679_CR12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41409-018-0290-6","volume":"54","author":"E Martelin","year":"2019","unstructured":"Martelin E, Volin L, It\u00e4l\u00e4-Remes M et al (2019) Incidence and risk factors of secondary cancers after allogeneic stem cell transplantation: analysis of a single centre cohort with a long follow-up. Bone Marrow Transplant 54:334\u2013337. https:\/\/doi.org\/10.1038\/s41409-018-0290-6","journal-title":"Bone Marrow Transplant"},{"key":"5679_CR13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1067\/moe.2001.115392","volume":"91","author":"CS Miller","year":"2001","unstructured":"Miller CS, Johnstone BM (2001) Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982\u20131997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91:622\u2013635. https:\/\/doi.org\/10.1067\/moe.2001.115392","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"5679_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-138927","volume":"136","author":"I Novitzky-Basso","year":"2020","unstructured":"Novitzky-Basso I, Pasic I, Al-Shaibani Z et al (2020) Increased risk of secondary malignancy associated with the use of azathioprine for chronic graft-versus-host disease treatment. Blood 136:1\u20132. https:\/\/doi.org\/10.1182\/blood-2020-138927","journal-title":"Blood"},{"key":"5679_CR15","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/BLOOD-2008-05-158782","volume":"113","author":"JD Rizzo","year":"2009","unstructured":"Rizzo JD, Curtis RE, Soci\u00e9 G et al (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113:1175\u20131183. https:\/\/doi.org\/10.1182\/BLOOD-2008-05-158782","journal-title":"Blood"},{"key":"5679_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.seminhematol.2011.10.013","volume":"49","author":"G Soci\u00e9","year":"2012","unstructured":"Soci\u00e9 G, Rizzo JD (2012) Second solid tumors: screening and management guidelines in long-term survivors after allogeneic stem cell transplantation. Semin Hematol 49:4\u20139. https:\/\/doi.org\/10.1053\/j.seminhematol.2011.10.013","journal-title":"Semin Hematol"},{"key":"5679_CR17","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"key":"5679_CR18","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2004-01-0200","volume":"104","author":"BL Stewart","year":"2004","unstructured":"Stewart BL, Storer B, Storek J et al (2004) Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 104:3501\u20133506. https:\/\/doi.org\/10.1182\/blood-2004-01-0200","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05679-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05679-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05679-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T11:11:01Z","timestamp":1713006661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05679-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["5679"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05679-5","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,22]]},"assertion":[{"value":"3 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gruber Isabella, Appel Katharina, Koelbl Oliver and Edinger Matthias have no financial or non-financial interests to disclose. Wolff Daniel received research support from Novartis and honoraria from Novartis, Sanofi, Incyte, Behring, Neovii, Takeda and Mallinckrodt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Gruber Isabella, Appel Katharina, Koelbl Oliver and Edinger Matthias have no financial or non-financial interests to disclose. Wolff Daniel received research support from Novartis and honoraria from Novartis, Sanofi, Incyte, Behring, Neovii, Takeda and Mallinckrodt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University Regensburg (number, 20-1810-101, date, February 10, 2021).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"152"}}